Regional Differences in Prevalence of HIV-1 Discordance in Africa and Enrollment of HIV-1 Discordant Couples into an HIV-1 Prevention Trial

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation

Published Version
doi:10.1371/journal.pone.0001411

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:4584789

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Regional Differences in Prevalence of HIV-1 Discordance in Africa and Enrollment of HIV-1 Discordant Couples into an HIV-1 Prevention Trial

Jairam R. Lingappa1*, Barrot Lambdin2, Elizabeth Ann Bukusi3, Kenneth Ngure4, Linda Kavuma5, Mubiana Inambao6, William Kanweka7, Susan Allen8, James N. Kiarie9, Joseph Makhema10, Edwin Were11, Rachel Manongi12, David Coetzee13, Guy de Bruyn14, Sinead Delany-Moret15, Amalia Magaret16, Nelly Mugol14, Andrew Mujugira1, Patrick Ndase1, Connie Celum1, for the Partners in Prevention HSV-2/HIV Transmission Study Group

1 University of Washington, Department of Medicine, Seattle, Washington, United States of America, 2 University of Washington, Department of Epidemiology, Seattle, Washington, United States of America, 3 Center for Microbiology Research Kenya Medical Research Institute, Nairobi, Kenya, 4 Kenyatta National Hospital, Nairobi, Kenya, 5 Infectious Disease Institute, Makerere University Medical School, Kampala, Uganda, 6 Rwanda-Zambia HIV Research Group (RZHRG), Ndola, Zambia, 7 Rwanda-Zambia HIV Research Group (RZHRG), Kitwe, Zambia, 8 RZHRG and Emory University, Rollins School of Public Health, Atlanta, Georgia, United States of America, 9 University of Nairobi, Department of Obstetrics and Gynecology, Nairobi, Kenya, 10 Botswana-Harvard Partnership, Gaborone, Botswana, 11 Moi University, Department of Reproductive Health, Eldoret, Kenya, 12 Kilimanjaro Christian Medical Centre, Moshi, Tanzania, 13 Infectious Disease Epidemiology Unit, University of Cape Town, Cape Town, Republic of South Africa, 14 Perinatal HIV Research Unit, University of Witwatersrand, Johannesburg, Republic of South Africa, 15 Reproductive Health Research Unit, University of Witwatersrand, Johannesburg, Republic of South Africa, 16 University of Washington, Department of Laboratory Medicine, Seattle, Washington, United States of America

Background. Most HIV-1 transmission in Africa occurs among HIV-1-discordant couples (one partner HIV-1 infected and one uninfected) who are unaware of their discordant HIV-1 serostatus. Given the high HIV-1 incidence among HIV-1 discordant couples and to assess efficacy of interventions for reducing HIV-1 transmission, HIV-1 discordant couples represent a critical target population for HIV-1 prevention interventions and prevention trials. Substantial regional differences exist in HIV-1 prevalence in Africa, but regional differences in HIV-1 discordance among African couples, has not previously been reported. Methodology/Principal Findings. The Partners in Prevention HSV-2/HIV Transmission Trial (“Partners HSV-2 Study”), the first large HIV-1 prevention trial in Africa involving HIV-1 discordant couples, completed enrollment in May 2007. Partners HSV-2 Study recruitment data from 12 sites from East and Southern Africa were used to assess HIV-1 discordance among couples accessing couples HIV-1 counseling and testing, and to correlate with enrollment of HIV-1 discordant couples. HIV-1 discordance at Partners HSV-2 Study sites ranged from 8–31% of couples tested from the community. Across all study sites and, among all couples with one HIV-1 infected partner, almost half (49%) of couples were HIV-1 discordant. Site-specific monthly enrollment of HIV-1 discordant couples into the clinical trial was not directly associated with prevalence of HIV-1 discordance, but was modestly correlated with national HIV-1 counseling and testing rates and access to palliative care/basic health care (r = 0.74, p = 0.09). Conclusions/Significance. HIV-1 discordant couples are a critical target for HIV-1 prevention in Africa. In addition to community prevalence of HIV-1 discordance, national infrastructure for HIV-1 testing and healthcare delivery and effective community outreach strategies impact recruitment of HIV-1 discordant couples into HIV-1 prevention trials.

INTRODUCTION

Among the estimated 40 million people worldwide currently living with HIV-1 infection, 65% reside in sub-Saharan Africa [1], with heterosexual exposure as the primary mode of HIV transmission. Prior studies have found high rates of HIV-1 transmission occurring between HIV-discordant partners (where one partner is HIV- infected and one is HIV-uninfected) who are often in stable partnerships but unaware of both partner’s HIV-1 serostatus [2–4]. Recent data from Uganda indicate that 83% of HIV-infected men and 77% of HIV-infected women are or have been married [5]. Furthermore, among HIV-1 infected married persons, 75% of men and 96% of women report having had sex only with their spouse [5–7]. HIV-1 counseling and testing specifically adapted to couples including education about HIV-1 discordance rather than an individual-focused HIV-1 risk assessment and counseling can help reduce HIV-1 transmission [2,8,9]. This underscores that stable HIV-1-discordant African couples are a critical target for counseling and testing and evaluation of new prevention interventions.

Microbicides, vaccines, pre-exposure prophylaxis, male circumcision, HSV-2 suppression, and other interventions are currently under evaluation to increase the range of public health tools for HIV-1 prevention. Efficacy trials and public health implementation studies of these interventions will require tens of thousands of...
participants over the coming years. Prevention trials that recruit and follow HIV-1 discordant couples are of particular importance in evaluating interventions for reducing HIV-1 infectiousness while also permitting evaluation of biologic and behavioral factors in both the transmitting and susceptible host which modulate the risk of HIV-1 transmission.

There are unique challenges to conducting clinical trials with HIV-1-discordant couple cohorts. In particular, recruiting both partners to undergo HIV-1 counseling and testing together is difficult, as only 10–30% of persons in Africa who are tested for HIV-1 come as a couple [10]. This is in part due to the reluctance of men to be tested for HIV-1 in many parts of Africa, coupled with assumptions that their partner’s HIV-1 status is the same as theirs (which is referred to as ‘HIV-1 testing by proxy’). In addition, VCT counselors typically trained in individual VCT techniques are reluctant to engage in couples’ HIV-1 counseling and testing (CHCT) due to additional time required, for CHCT, skills needed for addressing other relationship issues that may be raised, and concerns about as well as the risk of domestic violence, abandonment or stigmatization if one but not both partners learn that they are HIV-1-infected [11–14]. Importantly, many HIV-1 counselors and couples have myths, misperceptions, and denial about HIV-1 discordance [9].

Between November 2004 and May 2007 we recruited a cohort of 3408 HIV-1-discordant couples from 14 sites in eastern and southern Africa into the Partners in Prevention HSV-2/HIV-1 Transmission Trial (“Partners HSV-2 Study”). Recruitment for this trial provided a unique opportunity to evaluate the prevalence of HIV-1 discordance in diverse African communities and identify factors correlating with recruitment of HIV-1-discordant couples.

METHODS

The Partners HSV-2 Study is designed to assess the impact of HSV-2 suppression with acyclovir (400 milligrams orally, twice daily) compared to placebo in reducing HIV-1-transmission among couples in which one partner is HIV-1/HSV-2 co-infected with a CD4 count ≥250 and not eligible for antiretroviral initiation, and their partner is HIV-1-uninfected (ClinicalTrials.gov ID # NCT00194519) [15–17]. In May 2007, 14 clinical trial sites in 7 countries in Eastern and Southern Africa completed screening of 7863 HIV-1 discordant couples and enrollment of 3408 HIV-1-discordant couples. Follow-up will continue through May 2008 to evaluate the efficacy of herpes suppression on reducing HIV-1 transmission to the initially HIV-1-uninfected partner.

Partners HSV-2 Study sites

Twelve of 14 Partners HSV-2 Study clinical trial sites recruited couples from the community; two sites (Kigali, Rwanda and Lusaka, Zambia) recruited couples from existing cohorts of HIV-1 discordant couples and therefore are not included in this analysis. Of the 12 sites, six are in Eastern Africa, including Nairobi, Thika, Kisumu and Eldoret, Kenya; Kampala, Uganda; and Moshi/Arusha, Tanzania; and six in Southern Africa, including Soweto, Orange Farm and Gugulethu, South Africa; Ndola and Kitwe, Zambia; and Gaborone, Botswana.

Partners HSV-2 Study recruitment methods

Couples HIV-1 Counseling and Testing (CHCT) All study sites used CHCT as the initial entry point for identifying discordant couples who could then be evaluated for study eligibility. Over 1000 community-based and study site counselors were trained through the Partners HSV-2 Study using a CDC, NIMH, Liverpool School of Tropical Medicine standardized CHCT curriculum that covered basic counseling methods, the importance of HIV-1-discordance, review of HIV-1 risk issues for couples and approaches to counseling couples testing discordant HIV-1-positive, discordant HIV-1-negative or HIV-1-discordant.

Partners HSV-2 Study Community Recruitment Couples were either recruited directly through community outreach from the Partners HSV-2 Study clinic including methods similar to those reported elsewhere [2,8,18,19], or indirectly through training of hundreds of community counselors in CHCT skills and collaboration with community voluntary counseling and testing (VCT) centers, antenatal and HIV-1 clinics, non-governmental organizations, and coupled with direct community outreach efforts with street theatre, one-to-one peer outreach, radio discussions, and other messages about CHCT in the community. These multiple strategies led to referral of interested HIV-1-discordant couples to the Partners HSV-2 Study clinics for additional counseling about HIV-1 discordance and screening for eligibility for the Partners HSV-2 Study.

CHCT and VCT Data Collection

Community-based CHCT HIV-1 testing data among couples was obtained from the principal community VCT centers who referred HIV-1-discordant couples to the Partners HSV-2 Study clinics and from testing of couples of unknown HIV-1 status at the Partners HSV-2 Study clinics. These data were collected at the Ndola and Kitwe, Zambia study sites from July 2005 through April 2006. For the remaining sites due to the additional coordination and efforts involved in data collection from multiple referring VCT centers, prescreening data was only collected between December 2006 and April 2007.

Prescreening data were used to calculate HIV-1 discordance, HIV-1 negative and HIV-1 positive concordance as a percentage of the total number of couples tested at those sites during the data collection time period and as a weighted regional HIV-1 discordance rate across sites on a country-specific basis, regionally (Eastern and Southern Africa) and across these 12 Partners HSV-2 Study sites.

As an indicator of the utilization of HIV-1 counseling and testing and basic health care services in participating countries, we used publicly accessible data from the United States President’s Emergency Program For AIDS Relief (PEPFAR) [20]. We defined the National HIV-1 Response Index (NHRI) as the sum of the annual number of individuals receiving HIV-1 counseling and testing and palliative and basic health care services (including TB/HIV-1) accessed in a country normalized to the estimated number of people living with HIV-1/AIDS (PLWHA).

RESULTS

Descriptive data for the 12 Partners HSV-2 Study sites participating in community-based recruitment of HIV-1-discordant couples are presented in Table 1. Study sites vary from high population-density cities and associated townships to smaller rural towns. Based on Partners HSV-2 Study prescreening data, the prevalence of stable HIV-1-discordant partnerships ranged from 8 to 31% of total couples tested at each study site. Overall, Eastern and Southern African sites reported 12% and 18% HIV-1 discordance, respectively, with 15% HIV-1 discordance found across the whole study. Among all couples tested who had at least one HIV-1 infected partner, the proportion of couples which were HIV-1-discordant varied by study sites from 36-85% with an overall rate of 49%.

Approximately, 51,900 couples were prescreened for HIV-1 serostatus by partnering collaborating VCT centers, clinics or at the Partners HSV-2 Study clinics. From this large community
Table 1. PreScreening Data and Other Characteristics of Partners HSV-2 Study Sites

<table>
<thead>
<tr>
<th>Country</th>
<th>Site</th>
<th>Local Pop*</th>
<th>HIV-1 Prevalence (%)</th>
<th>Couples Tested</th>
<th>HIV-1 Testing Results</th>
<th>HIV-1 Discordance Prevalence (% Couples Tested)</th>
<th>National HIV-1 Response Index (NHRI)@</th>
<th>Partners HSV-2 Study Monthly Enrollment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenya</td>
<td>Nairobi</td>
<td>4,000,000</td>
<td>9.9</td>
<td>624</td>
<td>84 (13)</td>
<td>49 (8)</td>
<td>491 (79)</td>
<td>13.6</td>
</tr>
<tr>
<td></td>
<td>Kisumu</td>
<td>320,000</td>
<td>15</td>
<td>3237</td>
<td>500 (15)</td>
<td>698 (22)</td>
<td>2039 (63)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thika</td>
<td>448,000</td>
<td>6–9</td>
<td>751</td>
<td>64 (9)</td>
<td>23 (3)</td>
<td>664 (88)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eldoret</td>
<td>450,000</td>
<td>6–9</td>
<td>383</td>
<td>29 (8)</td>
<td>40 (10)</td>
<td>314 (82)</td>
<td></td>
</tr>
<tr>
<td>Uganda</td>
<td>Kampala</td>
<td>1,200,000</td>
<td>13</td>
<td>2079</td>
<td>181 (9)</td>
<td>183 (9)</td>
<td>1715 (82)</td>
<td>8.7</td>
</tr>
<tr>
<td>Tanzania</td>
<td>Moshi/Arusha</td>
<td>145,000</td>
<td>9.6</td>
<td>477</td>
<td>56 (12)</td>
<td>10 (2)</td>
<td>411 (86)</td>
<td>11.7</td>
</tr>
<tr>
<td>S. Africa</td>
<td>Soweto</td>
<td>1,200,000</td>
<td>30</td>
<td>286</td>
<td>66 (23)</td>
<td>62 (22)</td>
<td>158 (55)</td>
<td>27.4</td>
</tr>
<tr>
<td></td>
<td>Orange Farm</td>
<td>500,000</td>
<td>30</td>
<td>525</td>
<td>145 (28)</td>
<td>89 (17)</td>
<td>290 (55)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gugulethu</td>
<td>340,000</td>
<td>27</td>
<td>315</td>
<td>97 (31)</td>
<td>55 (17)</td>
<td>163 (52)</td>
<td></td>
</tr>
<tr>
<td>Zambia</td>
<td>Ndola</td>
<td>636,000</td>
<td>20</td>
<td>2241</td>
<td>271 (12)</td>
<td>474 (21)</td>
<td>1496 (67)</td>
<td>14.2</td>
</tr>
<tr>
<td></td>
<td>Kitwe</td>
<td>675,000</td>
<td>20</td>
<td>2827</td>
<td>450 (16)</td>
<td>628 (22)</td>
<td>1749 (62)</td>
<td></td>
</tr>
<tr>
<td>Botswana</td>
<td>Gaborone</td>
<td>208,000</td>
<td>24</td>
<td>2589</td>
<td>522 (20)</td>
<td>241(9)</td>
<td>1826 (71)</td>
<td>20.1</td>
</tr>
</tbody>
</table>

*2004 or 2005 census data.

**From PEPFAR (http://www.pepfar.gov/): “National HIV-1 prevalence among adults aged 15–49” for each country listed.

Clinical trial recruitment also extended to outlying districts with total population of 0.75–1.5 million persons.


Total number of couples receiving HIV counseling and testing during previously defined recruitment periods: July 2005–April 2006 (Ndola and Kitwe, Zambia) and December 2006–April 2007 (all other Partners HSV-2 Study sites).

NHRI calculated from PEPFAR data (http://www.pepfar.gov/) as: ("#" individuals receiving counseling and testing in settings other than PMTCT in FY2006 + "#" HIV-1 infected individuals receiving palliative care/basic health care and support in FY2006 (including HIV-1/TB)/"#" Adults and children (age 0–49) living with HIV-1 at the end of 2005.

doi:10.1371/journal.pone.0001411.t001
CHCT effort, 7863 HIV-1-discordant couples were referred to Partners HSV-2 Study sites and screened for study eligibility, of whom 4178 met study eligibility criteria; 3408 couples were enrolled into the Partners HSV-2 Study. Thus, for each HIV-1-discordant couple enrolled in the clinical trial, over 15 couples (site range 4.4–42.1) were provided CHCT and learned their HIV-1 status and 1.9 HIV-1-discordant couples (site range 1.5–2.5) were screened for study eligibility. Despite HIV-1 discordance being more prevalent in Southern Africa, the site-specific Partners HSV-2 Study monthly enrollment rate was higher in Eastern compared to Southern African sites (15.1 versus 11.2 couples/month, respectively). Overall, HIV-1 discordance rates among couples tested in the community were not significantly correlated with site-specific monthly study enrollment rates (correlation coefficient -0.64, p = 0.16). There was a trend for an association between the country NHRI (Table 1) and average monthly site-specific enrollment of HIV-1 discordant couples into the Partners HSV-2 Study (correlation coefficient = 0.74, p = 0.09). Other PEPFAR-reported measures for dissemination of HIV-1 prevention information, such as persons accessing ABC (‘Abstinence, ‘Be faithful and use Condoms’) messages, as measured by PEPFAR, did not strongly correlate with study enrollment (correlation coefficient = 0.32, p = 0.54, data not shown).

DISCUSSION

HIV-1 discordance was highly prevalent in the 12 communities from Eastern and Southern Africa that participated in this multisite clinical trial of HSV-2 suppression to prevent HIV-1 transmission within HIV-1 discordant couples. Overall, among couples presenting for HIV-1 testing in which one partner was infected with HIV-1, 49% were identified as HIV-1-discordant. The prevalence of HIV-1 discordance has been documented previously in several African countries including in Zambia [21], Uganda [3], Kenya [22]. Significant regional differences in HIV-1 discordance have previously been reported among couples identified in the cross-sectional Four Cities study [22]. Notably, two sites, Ndola, Zambia and Kisumu, Kenya were included in both the Partners HSV-2 Study and the Four Cities Study and observed to have similar prevalence of HIV-1 discordance (12% versus 13% in Ndola and 16% versus 23% in Kisumu) 10 years apart and using different sampling methodologies. The continued high prevalence of HIV-1 discordance in diverse African sites underscores the public health importance of couples with HIV-1 discordant results for HIV-1 prevention. By facilitating CHCT training for almost 1000 counselors and heightening community awareness of HIV-1-discordance in 14 study sites located in seven countries, the Partners HSV-2 Study has demonstrated the feasibility of recruiting and counseling HIV-1 discordant couples in diverse regions of Africa. Building capacity for CHCT, with development of messages about testing as couples and the importance of HIV-1 discordance in HIV-1 transmission, is an important and sustainable public health initiative in Africa.

Interestingly, we found no statistically significant association between Partners HSV-2 Study enrollment rates and prevalence of HIV-1 discordance among couples in study site communities. We did find a trend for an association between site-specific average monthly study enrollment and the NHRI, a normalized measure of testing and care services accessed in a country. While difficulties in mobilizing men to be tested, HIV-1-associated stigma, and fears associated with disclosure of HIV-1 status remain ongoing challenges in recruiting HIV-discordant couples, the Partners HSV-2 Study recruitment experience suggests that enrolling HIV-1 discordant couples for a clinical trial is affected more by the availability of HIV-1 counseling, testing and palliative and basic healthcare services and support for HIV-infected persons than by a high prevalence of HIV-1 discordance. Notably, levels of community access to “ABCs” messages, as measured by PEPFAR, did not have an association with enrollment of HIV-1-discordant couples. This may arise from abstinence and condom use messages being viewed as less relevant to stable couples.

HIV-1 prevention trials involving HIV-1 discordant couples can be implemented in countries with less developed VCT infrastructure and lower HIV-1 testing rates. The community recruitment strategy utilized in the Ndola and Kisumu, Zambia sites, based on a model developed in Rwanda [2] and previously implemented in Lusaka, Zambia [21], was associated with high rates of enrollment despite relatively lower national levels of counseling and testing in Zambia. However, local factors impact the effectiveness of specific clinical trial recruitment strategies, and attempts to implement this recruitment model in other Partners HSV-2 Study sites were less successful in Zambia. Furthermore, recruitment costs were reduced if referrals were obtained from community VCTs.

In conclusion, HIV-1 discordant couples represent an important target population for HIV-1 prevention, given the high rates of HIV-1 transmission in couples that do not know or disclose their HIV-1 status. HIV-1 discordant couples are also a valuable population for clinical trials evaluating vaccines, microbicides and other HIV-1 prevention interventions. Our findings suggest that increased national access to HIV-1 counseling and testing services and health care can facilitate identification of HIV-1 discordant couples for prevention interventions and enrollment into HIV-1 prevention trials. In view of these public health benefits and the importance of identifying new prevention strategies to reduce HIV-1 transmission in Africa, it is of critical importance to enhance community mobilization to encourage couples to be tested for HIV-1 as couples rather than as individuals, expand training of counselors in CHCT techniques and counseling messages about HIV-1 discordance, and prioritize prevention for HIV-1-discordant couples in Africa.

ACKNOWLEDGMENTS

CHCT counselor training curricula were developed through a collaborative effort of the Rwanda-Zambia HIV-1 Research Group (Dr. Susan Allen, RZHRG, Emory, U. S. Centers for Disease Control and Prevention (Dr. Rebecca Bunnell, Global AIDS Program, Uganda), the Partners in Prevention Clinical Trial (Dr. Connie Celum, Principal Investigator, University of Washington) and Liverpool Voluntary Counseling and Testing (Dr. Miriam Taegtmeyer, Director). We also thank the acting Director, Kenya Medical Research Institute for assisting with study efforts for our Kisumu, Kenya study site and Dr. Jared Baeten (University of Washington) for his very lucid comments, critical eye and support for this manuscript.

We also acknowledge the intensive and unremitting efforts of study staff leading or having a major role in developing the local site recruitment for the Partners HSV-2 Study. These include: Josephine Odoyo and Joel Odundi (Kenya Medical Research Institute, Kisumu, Kenya); Peter Mwungi (Kenyatta National Hospital, Thika, Kenya); Edith Nakibo Chama, Kenneth Mugwanya, Rosetta Musoke, Edith Kibunika, Diego Izizinga, Gladys Kibukka, Charles Brown (Infectious Diseases Institute, Makerere University, Kampala, Uganda); Nafshi Opiyo and John Kinuthia (University of Nairobi, Nairobi, Kenya); Anchilla Owoor (Botswana-Harvard Partnership, Gaborone, Botswana); Joyce Baliddawa, Paul Ayuo, Solomon Nzioka, and Gatetwa Mungai (Moi University, Eldoret, Kenya) with John Siile, and Kara Wools Kallonistian (University of Indiana); Paul Magao, Mafiri Swai, Atemush Imere, Amina Mlay, Freedom Mavo, lucky Temu, George Mgonella, and Bastidi Bamba (Kilimanjaro Christian Medical Centre, Moshi, Tanzania); Mercy Kamupira (Infectious Disease Epidemiology Unit, University of Cape Town, Republic of South Africa); Shibonge Diadla, Lindi Nobangela, Naka Sibeko, Gugu Tshabalala, Thabo Scabelo, Gavin Robertson, and Ntombi Bandezi (Perinatal HIV-1 Discordance in Africa

HIV-1 Discordance in Africa

Thabo Seabelo, Gavin Robertson, and Ntombi Bandezi (Perinatal HIV-1 Discordance in Africa

PLoS ONE | www.plosone.org 4 January 2008 | Issue 1 | e1411
Partners in Prevention HSV-2/HIV Transmission Study Group:

**Kisumu, Kenya Site:**
- Craig Cohen (Co-Principal Investigator, University of California, San Francisco)
- Adam Readhead, Godspower Akpomemie, Jessica Arjun, Nkgolo Gegana, Thiliwe Mashapa, Dorcas Mahaso, Zama Shongwe, Gusta Francisco

**Nairobi, Kenya Site:**
- Grace John-Stewart (Co-Principal Investigator, University of Washington, Seattle, USA)

**Kampala, Uganda Site:**
- Careen Farquhar (Co-Principal Investigator, University of Western Ontario, London, Canada)
- Elly Katabira (Co-Principal Investigator, Infectious Disease Institute, Kampala, Uganda)

**Seattle, USA Site:**
- Grace John-Stewart (Co-Principal Investigator, University of Washington, Seattle, USA)
- Carey Farquhar (Co-Principal Investigator, University of Washington, Seattle, USA)
- Francisco Cohen (Co-Principal Investigator, University of California, San Francisco)

**Kisumu, Kenya Site:**
- Partnervs in Prevention HSV-2/HIV Transmission Study Group:
  - Yaw Ado-Sarkodie, Nonkululeko Mlala, Mamazane Maduna, Adam Readhead, Godspower Akpomemie, Jessica Arjun, Nkgolo Gegana, Thiliwe Mashapa, Dorcas Mahaso, Zama Shongwe, Gusta Francisco

**Albany, USA Site:**
- Allen Ronald (Co-Principal Investigator, University of Manitoba, Manitoba, Canada)

**Gaborone, Botswana Site:**
- Allen Ronald (Co-Principal Investigator, University of Manitoba, Manitoba, Canada)

**Cape Town, Republic of South Africa Site:**
- Alana deKock (Co-Principal Investigator, Infectious Disease Epidemiology Unit, University of Cape Town, Cape Town, Republic of South Africa)

**Soweto, Republic of South Africa Site:**
- Glenda Gray (Co-Principal Investigator, Perinatal HIV Research Unit, Univ. of Witwatersrand, Johannesburg, Republic of South Africa)

**Orange Farm, Republic of South Africa Site:**
- Helen Rees, (Co-Principal Investigator, Reproductive Health Research Unit, Univ. of Witwatersrand, Johannesburg, Republic of South Africa)

Author Contributions

Conceived and designed the experiments: CC WK JL JK EB KN LK MI SA EB DC Gd SD NM AM PN. Performed the experiments: CC WK JL AM EB BL EB KN LK MI JM EW RM DC Gd SD NM AM PN. Analyzed the data: JL BL. Contributed reagents/materials/analysis tools: SA. Wrote the paper: CC WK JL AM JK BL EB KN LK MI SA JM EW RM DC Gd SD NM AM PN.

**REFERENCES**


